Results 21 to 30 of about 1,816 (199)

Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study [PDF]

Journal of Ophthalmic Inflammation and Infection
Background Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve.
Maria Madeira, Ana Cabugueira, Helena Urbano, Miguel Cordeiro, Marta Guedes   +4 more
doaj   +2 more sources

Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidence [PDF]

Global & Regional Health Technology Assessment, 2017
Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidenceIntroductionTreatment options for macular edema include intravitreal corticosteroids.
Marco Marchetti, Luz Irene Urbina, Marco Oradei, Matteo Ruggeri, Pierluigi Navarra   +4 more
doaj   +4 more sources

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review [PDF]

Journal of International Medical Research, 2019
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti ...
Horace Massa, Anindyt M. Nagar, Athanasios Vergados, Panagiotis Dadoukis, Sudeshna Patra, Georgios D. Panos   +5 more
doaj   +5 more sources

Delayed-Onset Wound Leakage and Endophthalmitis After Intravitreal Implantation of Fluocinolone Acetonide. [PDF]

J Vitreoretin Dis
Purpose: To report an unusual case of delayed endophthalmitis in a young patient treated for serpiginous choroidopathy. Methods: A single case was reviewed. Results: An 18-year-old patient developed endophthalmitis 3 years after ...
Chang PS, Yu JH, Chun DW, Ali MH, Levinson JD, Do BK, Melamud A.   +6 more
europepmc   +3 more sources

Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments [PDF]

Journal of Ophthalmic Inflammation and Infection
Background This study evaluates the long-term efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone ...
Ana Margarida Ferreira, Marta Inês Silva, Sónia Torres-Costa, Cláudia Oliveira-Ferreira, Ana Catarina Pedrosa, Luís Figueira, Joana Rodrigues Araújo   +6 more
doaj   +2 more sources

Prevalence and Risk Factors of Ocular Hypertension Following Fluocinolone Acetonide (Iluvien®) Intravitreal Injections: The “SAFAC” Study [PDF]

Ophthalmology and Therapy
Introduction The aim of this real-life study was to analyze the prevalence and risk factors of ocular hypertension (OHT) after fluocinolone acetonide implant (FAc-I) intravitreal injections in the treatment of macular edema of various etiologies. Methods
Yasmine Serrar, Lucas Sejournet, Benoît Allignet, Sami Bounetta, Marwa Deiri, Chloé Gullon, Ariane Malclès, Philippe Denis, Thibaud Mathis, Laurent Kodjikian   +9 more
doaj   +2 more sources

Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema [PDF]

Journal of Vitreoretinal Diseases
Christine Morozova, Lucas Humayun, David S Boyer   +2 more
exaly   +2 more sources

Fluocinolone Implant for Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome: A Case Report

Case Reports in Ophthalmology, 2021
Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is a rare and progressive disorder that predominantly affects both the eyes of young female individuals and can threaten visual function.
Lucía Moreno-Castro, Gerardo Pedro García-García, Joseba Artaraz, Alex Fonollosa   +3 more
doaj   +1 more source

Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study

Acta Ophthalmologica, Volume 101, Issue 1, Page 22-33, February 2023., 2023
Abstract Purpose To evaluate topical dexamethasone ophthalmic suspension OCS‐01 (Oculis SA, Lausanne, Switzerland) in diabetic macular edema (DME). Methods This was a multicenter, double‐masked, parallel‐group, randomized, Phase 2 study. Patients aged 18–85 years with DME of <3 years duration, ETDRS central subfield thickness ≥ 310 μm by SD‐OCT, and ...
Einar Stefansson, Thorstein Loftsson, Michael Larsen, András Papp, Kai Kaarniranta, Marion R. Munk, Pravin Dugel, Ramin Tadayoni, DX‐211 study group   +8 more
wiley   +1 more source

Diabetic Macular Oedema Guidelines: An Australian Perspective

Journal of Ophthalmology, Volume 2023, Issue 1, 2023., 2023
The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy ...
Yew Sen Yuen, Jagjit Singh Gilhotra, Michelle Dalton, Jaskirat S. Aujla, Hemal Mehta, Sanj Wickremasinghe, Gurmit Uppal, Jennifer Arnold, Fred Chen, Andrew Chang, Samantha Fraser-Bell, Lyndell Lim, Janika Shah, Ellie Bowditch, Geoffrey K. Broadhead, Paolo Milani   +15 more
wiley   +1 more source